Document:

Exhibit 10.10

 

SUBSCRIPTION
AGREEMENT

 

	To:	Inhibikase Therapeutics, Inc.

        3350 Riverwood Parkway, Suite
        1900

        Atlanta, GA 30339

        Attn: Chief Executive Officer

	 	 
	From:	[NAME]

        [ADDRESS]

        [ADDRESS]

 

This Subscription
Agreement (this “Agreement”) is being delivered to the subscriber identified on the signature page to this
Agreement (the “Subscriber”) in connection with its investment in the Common Stock, $[PRICE] per share, of
Inhibikase Therapeutics, Inc., a Delaware corporation (the “Company”).

 

1.            
SUBSCRIPTION

 

Subject to the conditions
set forth in Section 2 hereof, the Subscriber hereby subscribes for and agrees to subscribe for those shares of Common Stock (the
 “Shares”) indicated on page 7 hereof on the terms and conditions described herein.

 

2.            
SUBSCRIBER’S REPRESENTATIONS, WARRANTIES AND COVENANTS

 

Subscriber hereby acknowledges,
agrees with and represents, warrants and covenants to the Company, as follows:

 

(a)              
The Subscriber has full power and authority to enter into this Agreement, the execution and delivery of which has been
duly authorized, if applicable, and this Agreement constitutes a valid and legally binding obligation of the Subscriber.

 

(b)              
The Subscriber acknowledges its understanding that the sale of the Shares is intended to be exempt from registration under
the Securities Act of 1933, as amended (the “Securities Act”), by virtue of Section 4(2) of the Securities
Act and the provisions of Regulation D promulgated thereunder (“Regulation D”). In furtherance thereof, the
Subscriber represents and warrants to the Company and its affiliates as follows:

 

(i)                
The Subscriber realizes that the basis for the exemption from registration may not be available if, notwithstanding the
Subscriber’s representations contained herein, the Subscriber is merely acquiring the Shares for a fixed or determinable
period in the future, or for a market rise, or for sale if the market does not rise. The Subscriber does not have any such intention.

 

(ii)               
The Subscriber realizes that the basis for exemption would not be available if the investment is part of a plan or scheme
to evade registration provisions of the Securities Act or any applicable state or federal securities laws.

 

    

     

    

 

(iii)              
 The Subscriber is acquiring the Shares solely for the Subscriber’s own beneficial account, for investment purposes,
and not with a view towards, or resale in connection with, any distribution of the Shares.

 

(iv)             
The Subscriber has the financial ability to bear the economic risk of the Subscriber’s investment, has adequate means
for providing for its current needs and contingencies, and has no need for liquidity with respect to an investment in the Company.

 

(v)              
The Subscriber and the Subscriber’s attorney, accountant, purchaser representative and/or tax advisor, if any (collectively,
the “Advisors”) has such knowledge and experience in financial and business matters as to be capable of evaluating
the merits and risks of a prospective investment in the Shares. If other than an individual, the Subscriber also represents it
has not been organized solely for the purpose of acquiring the Shares.

 

(vi)              
The Subscriber (together with its Advisors, if any) has received all documents reasonably requested by the Subscriber,
if any, has carefully reviewed them and understands the information contained therein, prior to the execution of this Agreement.

 

(c)              
The Subscriber is not relying on the Company or any of its employees, agents, sub-agents or advisors with respect to economic
considerations involved in this investment. The Subscriber has relied on the advice of, or has consulted with, only its Advisors.
Each Advisor, if any, is capable of evaluating the merits and risks of an investment in the Shares, and each Advisor, if any,
has disclosed to the Subscriber in writing (a copy of which is annexed to this Agreement) the specific details of any and all
past, present or future relationships, actual or contemplated, between the Advisor and the Company or any affiliate or sub-agent
thereof.

 

(d)              
The Subscriber represents, warrants and agrees that he, she or it will not sell or otherwise transfer any Shares without
registration under the Securities Act or an exemption therefrom, and fully understands and agrees that the Subscriber must bear
the economic risk of its purchase because, among other reasons, the Shares have not been registered under the Securities Act or
under the securities laws of any state and, therefore, cannot be resold, pledged, assigned or otherwise disposed of unless they
are subsequently registered under the Securities Act and under the applicable securities laws of such states, or an exemption
from such registration is available. In particular, the Subscriber is aware that the Shares are “restricted securities,”
as such term is defined in Rule 144 promulgated under the Securities Act (“Rule 144”), and they may not be
sold pursuant to Rule 144 unless all of the conditions of Rule 144 are met. The Subscriber also understands that the Company is
under no obligation to register the Shares on behalf of the Subscriber or to assist the Subscriber in complying with any exemption
from registration under the Securities Act or applicable state securities laws. The Subscriber understands that any sales or transfers
of the Shares are further restricted by state securities laws and the provisions of this Agreement.

 

(e)              
No oral or written representations or warranties have been made to the Subscriber by the Company or any of its officers,
employees, agents, sub-agents, affiliates, advisors or subsidiaries, other than any representations of the Company contained herein,
and in subscribing for the Shares, the Subscriber is not relying upon any representations other than those contained herein.

 

    -2-

     

    

 

(f)               
The Subscriber understands and acknowledges that its purchase of the Shares is a speculative investment that involves a
high degree of risk and the potential loss of their entire investment and, in particular, acknowledges that the Company has a
limited operating history and is engaged in a highly competitive business.

 

(g)              
The Subscriber’s overall commitment to investments that are not readily marketable is not disproportionate to the
Subscriber’s net worth, and an investment in the Shares will not cause such overall commitment to become excessive.

 

(h)              
The Subscriber understands and agrees that the certificates for the Shares shall bear substantially the following legend
until (i) such Shares shall have been registered under the Securities Act and effectively disposed of in accordance with a registration
statement that has been declared effective or (ii) in the opinion of counsel for the Company, such Shares may be sold without
registration under the Securities Act, as well as any applicable “blue sky” or state securities laws:

 

THE SECURITIES REPRESENTED
BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
OR ANY APPLICABLE STATE SECURITIES LAWS. SUCH SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES AND MAY NOT BE OFFERED FOR
SALE, SOLD, TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FILED BY THE ISSUER WITH
THE U.S. SECURITIES AND EXCHANGE COMMISSION COVERING SUCH SECURITIES UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL SATISFACTORY
TO THE ISSUER THAT SUCH REGISTRATION IS NOT REQUIRED.

 

(i)                
Neither the Securities and Exchange Commission (the “SEC”) nor any state securities commission has approved
the Shares or passed upon or endorsed the merits of an investment therein. There is no government or other insurance covering
any of the Shares.

 

(j)                
The Subscriber and its Advisors, if any, have had a reasonable opportunity to ask questions of and receive answers from
a person or persons acting on behalf of the Company concerning the Shares and the business, financial condition, results of operations
and prospects of the Company, and all such questions have been answered to the full satisfaction of the Subscriber and its Advisors,
if any.

 

(k)              
The Subscriber is unaware of, is in no way relying on, and did not become aware of the Company’s offering of the
Shares through or as a result of, any form of general solicitation or general advertising including, without limitation, any article,
notice, advertisement or other communication published in any newspaper, magazine or similar media or broadcast over television
or radio, or electronic mail over the Internet, and is not subscribing for Shares and did not become aware of the Company’s
offering of the Shares through or as a result of any seminar or meeting to which the Subscriber was invited by, or any solicitation
of a subscription by, a person not previously known to the Subscriber in connection with investments in securities generally.

 

    -3-

     

    

 

(l)                
The Subscriber has taken no action that would give rise to any claim by any person for brokerage commissions, finders’
fees or the like relating to this Agreement or the transactions contemplated hereby.

 

(m)             
The Subscriber acknowledges that any estimates or forward-looking statements or projections furnished by the Company to
the Subscriber were prepared by the management of the Company in good faith, but that the attainment of any such projections,
estimates or forward-looking statements cannot be guaranteed by the Company or its management and should not be relied upon.

 

(n)              
This Agreement is not enforceable by the Subscriber unless it has been accepted by the Company, and the Subscriber acknowledges
and agrees that the Company reserves the right to reject any subscription for any reason.

 

(o)              
The Subscriber will indemnify and hold harmless the Company and, where applicable, its directors, officers, employees,
agents, advisors, affiliates and shareholders, and each other person, if any, who controls any of the foregoing from and against
any and all loss, liability, claim, damage and expense whatsoever (including, but not limited to, any and all fees, costs and
expenses whatsoever reasonably incurred in investigating, preparing or defending against any claim, lawsuit, administrative proceeding
or investigation whether commenced or threatened) (a “Loss”) arising out of or based upon any representation
or warranty of the Subscriber contained herein or in any document furnished by the Subscriber to the Company in connection herewith
being untrue in any material respect or any breach or failure by the Subscriber to comply with any covenant or agreement made
by the Subscriber herein or therein; provided, however, that the Subscriber shall not be liable for any Loss that in the
aggregate exceeds such Subscriber’s Aggregate Purchase Price tendered hereunder.

 

(p)              
The Subscriber is, and on each date on which the Subscriber continues to own the Shares will be, an “Accredited Investor”
as defined in Rule 501(a) under the Securities Act.

 

(q)              
The Subscriber represents, warrants and covenants that: (i) it is not, nor is any person or entity controlling, controlled
by or under common control with Subscriber, included on the List of Specially Designated Nationals and Blocked Persons maintained
by the U.S. Treasury Department’s Office of Foreign Assets ControlI (“OFAC”), as such list may be amended from time to time (such persons or entities are collectively referred
to as “Prohibited Persons”), and (ii) to the extent Subscriber has any beneficial owners, (1) it has carried
out thorough due diligence to establish the identities of such beneficial owners, (2) based on such due diligence, Subscriber
reasonably believes that no such beneficial owners are Prohibited Persons, (3) it holds the evidence of such identities and status
and will maintain all such evidence for at least five years from the date of Subscriber’s complete withdrawal from the Company,
and (4) it will make available such information and any additional information requested by the Company that is required under
applicable regulations. If any of the foregoing representations, warranties or covenants ceases to be true or if the Company no
longer reasonably believes that it has satisfactory evidence as to their truth, notwithstanding any other agreement to the contrary,
the Company may, in accordance with applicable regulations, freeze Subscriber’s investment, or Subscriber’s investment
may immediately be involuntarily withdrawn by the Company, and the Company may also be required to report such action and to disclose
Subscriber’s identity to OFAC or other authorities. Subscriber understands and agrees that any withdrawal proceeds paid
to it will be paid to the same account from which Subscriber’s investment in the Company was originally remitted, unless
the Company, in its sole discretion, agrees otherwise.

 

 

I The OFAC list may be accessed on the
web at http://www.treas.gov/ofac.

 

    -4-

     

    

 

3.            
THE COMPANY’S REPRESENTATIONS, WARRANTIES AND COVENANTS

 

The Company hereby
acknowledges, agrees with and represents, warrants and covenants to the Subscriber, as follows:

 

(a)              
The Company has the corporate power and authority to execute and deliver this Agreement and to perform its obligations
hereunder. This Agreement has been duly authorized, executed and delivered by the Company and is valid, binding and enforceable
against the Company in accordance with its terms.

 

(b)              
The Shares to be issued to the Subscriber pursuant to this Agreement, when issued and delivered in accordance with the
terms of this Agreement, will be duly and validly issued and fully paid and non-assessable.

 

(c)              
Neither the execution and delivery nor the performance of this Agreement by the Company will conflict with the Company’s
organizational materials, as amended to date, or result in a breach of any terms or provisions of, or constitute a default under,
any material contract, agreement or instrument to which the Company is a party or by which the Company is bound.

 

(d)              
Any information furnished by the Company in connection herewith is true and correct in all material respects as of its
date.

 

(e)              
The Company acknowledges and agrees that the Subscriber is acting solely in the capacity of an arm’s length purchaser
with respect to the Shares and the transactions contemplated hereby. The Company further acknowledges that the Subscriber is not
acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to this Agreement and the
transactions contemplated hereby and any advice given by the Subscriber or any of its representatives or agents in connection
with this Agreement and the transactions contemplated hereby is merely incidental to the Subscriber’s purchase of the Shares.
The Company further represents to the Subscriber that the Company’s decision to enter into this Agreement has been based
solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.

 

4.            
[RESERVED.]

 

5.            
NOTICES TO THE SUBSCRIBER

 

(a)              
THE SHARES OFFERED HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OR THE SECURITIES LAWS OF ANY STATE AND
ARE BEING OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH LAWS. THE
SHARES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SEC, ANY STATE SECURITIES COMMISSION OR OTHER REGULATORY AUTHORITY, NOR HAVE
ANY OF THE FOREGOING AUTHORITIES PASSED UPON OR ENDORSED THE MERITS OF THIS OFFERING OR THE ACCURACY OR ADEQUACY OF ANY INFORMATION
FURNISHED IN CONNECTION WITH THIS OFFERING. ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL.

 

    -5-

     

    

 

(b)              
THE SHARES OFFERED HEREUNDER ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD
EXCEPT AS PERMITTED UNDER THE SECURITIES ACT, AND APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM.
THE SUBSCRIBER SHOULD BE AWARE THAT IT MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD
OF TIME.

 

6.            
MISCELLANEOUS PROVISIONS

 

(a)              
Modification. Neither this Agreement, nor any provisions hereof, shall be waived, modified, discharged or terminated
except by an instrument in writing signed by the party against whom any waiver, modification, discharge or termination is sought.

 

(b)              
Survival. The representations, warranties and agreement of the Subscriber and the Company made in this Agreement
shall survive the execution and delivery of this Agreement and the delivery of the Shares.

 

(c)              
Notices. Any party may send any notice, request, demand, claim or other communication hereunder to the Subscriber
at the address set forth on the signature page of this Agreement or to the Company at the address set forth above using any means
(including personal delivery, expedited courier, messenger service, fax, ordinary mail or electronic mail), but no such notice,
request, demand, claim or other communication will be deemed to have been duly given unless and until it actually is received
by the intended recipient. Any party may change the address to which notices, requests, demands, claims and other communications
hereunder are to be delivered by giving the other parties written notice in the manner set forth.

 

(d)              
Binding Effect. Except as otherwise provided herein, this Agreement shall be binding upon, and inure to the benefit
of, the parties to this Agreement and their heirs, executors, administrators, successors, legal representatives and assigns. If
the Subscriber is more than one person or entity, the obligation of the Subscriber shall be joint and several and the agreements,
representations, warranties and acknowledgments contained herein shall be deemed to be made by, and be binding upon, each such
person or entity and its heirs, executors, administrators, successors, legal representatives and assigns. This Agreement sets
forth the entire agreement and understanding between the parties as to the subject matter thereof and merges and supersedes all
prior discussions, agreements and understandings of any and every nature among them.

 

(e)              
Assignability. This Agreement is not transferable or assignable by the Subscriber.

 

    -6-

     

    

 

(f)               
 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Georgia,
without giving effect to conflicts of law principles.

 

(g)              
Jurisdiction and Venue. The Company and the Subscriber hereby agree that any dispute that may arise between them
arising out of or in connection with this Agreement shall be adjudicated before a court located in the County of Cobb, State of
Georgia, and they hereby submit to the exclusive jurisdiction of the state courts of the County of Cobb, State of Georgia or federal
courts in and for the Northern District of Georgia, as applicable, with respect to any action or legal proceeding commenced by
any party, and irrevocably waive any objection they now or hereafter may have respecting the venue of any such action or proceeding
brought in such a court or respecting the fact that such court is an inconvenient forum, relating to or arising out of this Agreement
or any acts or omissions relating to the sale of the securities hereunder, and consent to the service of process in any such action
or legal proceeding by means of registered or certified mail, return receipt requested, postage prepaid, in care of the address
set forth herein or such other address as either party shall furnish in writing to the other.

 

IN WITNESS WHEREOF,
the Subscriber has executed this Agreement effective as of [DATE].

 

	Shares subscribed for

        [NUMBER] Shares of

        Company common stock
	Subscription Price

        $[PRICE]

 

    -7-

     

    

 

Manner in which Title is to be held (Please
Check One):

 

	1.	 	 	Individual	6.	 	 	Trust/Estate/Pension or Profit Sharing Plan
	2.	 	 	Joint Tenant with Right of Survivorship	7.	 	 	As Custodian for
	 	 	 	 	 	 	 	 
	3.	 	 	Married Community Property	 	 	 	Under the Uniform Gift to Minors
	4.	 	 	Tenants in Common	 	 	 	Act of the State of             
	5.	 	 	Corporation/Partnership/Limited Liability Company	8.	 	 	Married Separate Property
	 	 	 	 	9.	 	 	Tenants by the Entirety

 

Exact Name in Which Title is to be Held

  

	[NAME]	 	 
	Name (Please Print)	 	Name of Additional Purchaser
	 	 	 
	[ADDRESS]	 	 
	Residence: Number and Street	 	Address of Additional Purchaser
	 	 	 
	[ADDRESS]	 	 
	City, State and Zip Code	 	City, State and Zip Code
	 	 	 
	SS/EIN Identification Number	 	 
	 	 	Telephone Number
	[PHONE NUMBER]	 	 
	Telephone Number	 	 
	 	 	Fax Number (if available)
	 	 	 
	Fax Number (if available)	 	 
	 	 	E-Mail (if available)
	[EMAIL ADDRESS]	 	 
	E-Mail (if available)	 	 
	 	 	(Signature of Additional Purchaser)
	 	 	 
	(Signature)	 	 

  

    -8-

     

    

 

ACCEPTANCE

OF

SUBSCRIPTION

 

The undersigned, as
President and Chief Executive Officer (“CEO”) of Inhibikase Therapeutics, Inc. (“Company”), hereby accepts
and agrees to on behalf of Company the foregoing Subscription of [NAME] (the “Subscriber”) for [NUMBER] shares of
Company’s Common Stock for and in consideration for the consideration described therein.

 

IN WITNESS WHEREOF,
the undersigned, as President and CEO, has accepted such Subscription on behalf of Company as of [DATE].

 

	 	Inhibikase Therapeutics, Inc.
	 	 
	 	By:	 
	 	Name:	Milton Werner, Ph.D.
	 	Title:	President & CEO

 

    -9-

     

    

 

INVESTOR
QUESTIONNAIRE

 

Instructions: Check all boxes below
which correctly describe you.

 

	o	You are a natural person who had an individual income in
    excess of $200,000 in each of the two most recent years or joint income with your spouse in excess of $300,000 in each of
    the two most recent years, and who has a reasonable expectation of reaching the same income level in the current year.
	 	 
	o	You are a natural person
    whose individual net worth, or joint net worth with your spouse, exceeds $1,000,000 at the time of your subscription for and
    purchase of the Shares.
	o	You are an entity in which
    all of the equity owners are persons or entities described in one of the preceding paragraphs.
	o	You are an organization described in Section 501(c)(3) of the Internal
    Revenue Code of 1986, as amended (the “Code”), a corporation, Massachusetts or similar business trust or
    a partnership, in each case not formed for the specific purpose of making an investment in the Shares and its underlying assets
    are in excess of $5,000,000.
	 	 
	o	You are a trust, with total
    assets in excess of $5,000,000, not formed for the specific purpose of acquiring the Shares and whose subscription for and
    purchase of the Shares is directed by a sophisticated person as described in Rule 506(b)(2)(ii) of Regulation D.
	o	You are (i) a bank, as defined
    in Section 3(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), (ii) a savings and
    loan association or other institution, as defined in Section 3(a)(5)(A) of the Securities Act, whether acting in an individual
    or fiduciary capacity, (iii) a broker or dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934,
    as amended (the “Exchange Act”), (iv) an insurance company as defined in Section 2(13) of the Securities
    Act, (v) an investment company registered under the Investment Company Act of 1940, as amended (the “Investment Company
    Act”), (vi) a business development company as defined in Section 2(a)(48) of the Investment Company Act, (vii) a
    Small Business Investment Company licensed by the U.S.  Small Business Administration under Section 301 (c) or (d)
    of the Small Business Investment Act of 1958, as amended, (viii) a plan established and maintained by a state, its
    political subdivisions, or an agency or instrumentality of a state or its political subdivisions, for the benefit of its employees
    and you have total assets in excess of $5,000,000, or (ix) an employee benefit plan within the meaning of the Employee Retirement
    Income Security Act of 1974, as amended (“ERISA”) and (1) the decision that you shall subscribe for and
    purchase the Shares is made by a plan fiduciary, as defined in Section 3(21) of ERISA, which is either a bank, savings and
    loan association, insurance company, or registered investment adviser, or (2) you have total assets in excess of $5,000,000
    and the decision that you shall subscribe for and purchase the Shares is made solely by persons or entities that are accredited
    investors, as defined in Rule 501 of Regulation D promulgated under the Securities Act (“Regulation D”)
    or (3) you are a self-directed plan and the decision that you shall subscribe for and purchase the Shares is made solely by
    persons or entities that are accredited investors.

 

    -10-

     

    

 

	o	You are a private
    business development company as defined in Section 202(a)(22) of the Investment Advisers Act of 1940, as amended.
	o	You are a director or executive officer of Inhibikase Therapeutics,
    Inc.

 

Check all boxes below which correctly
describe you.

 

With respect to this investment in the
Shares, your:

 

	Investment
    Objectives	o  Aggressive
    Growth	o  Speculation
	 	 	 
	Rick
    Tolerance:	o  Low
    Risk	o  Moderate
    Risk
	 	 	 
	 	o  High
    Risk	 

 

Are you associated with a FNRA Member
Firm?    o Yes    o
No

 

Your initials (purchaser and co-purchaser,
if applicable) are required for each item below:

 

	 	 	 	I/We understand
    that this investment is not guaranteed.
	 	 	 	I/We are aware that this
    investment is not liquid.
	 	 	 	I/We are sophisticated in
    financial and business affairs and are able to evaluate the risks and merits of an investment in the Company and the Shares.
	 	 	 	I/We confirm that this investment is considered “high risk.”
    (This type of investment is considered high risk due to the inherent risks including lack of liquidity and lack of diversification.  Success
    or failure of private placements such as this is dependent on the corporate issuer of these securities and is outside the
    control of the investors.  While potential loss is limited to the amount invested, such loss is possible.)

 

The Subscriber hereby
represents and warrants that all of its answers to this Investor Questionnaire are true as of the date of its execution of the
Subscription Agreement pursuant to which it purchased Shares.

 

	 	 	 
	Name of Purchaser [please print]	 	Name of Co-Purchaser [please print]
	 	 	 
	 	 	 
	 	 	 
	Signature of Purchaser	 	Signature of Co-Purchaser

 

    -11-Exhibit 10.11

 

 

July 19, 2018

 

Joseph Ventures Allium LLC

c/o Michael P. Ross

300 Central Park West, Apt. 15-C2

New York, NY 10024-1593

 

	Re:	Side Letter

 

Reference is made to that certain Subscription
Agreement (the “Subscription Agreement”) between Inhibikase Therapeutics, Inc. (the “Company”) and Joseph
Ventures Allium LLC (the “Subscriber”). Capitalized terms used but not defined herein shall have the meanings ascribed
to such terms in the Subscription Agreement.

 

The Company is entering into this letter
agreement (this “Letter Agreement”) with Subscriber in connection with the transaction contemplated by the Subscription
Agreement. Accordingly, in consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency
of which is hereby acknowledged, the undersigned hereby agree as follows.

 

Notwithstanding anything to the contrary
set forth in the Subscription Agreement:

 

1.                  In
the event that the Company issues and sells (the “Sale”) Common Stock, or securities convertible into Common
Stock, to one or more institutional, venture capital, or private investors, or employees, consultants or affiliates (the
 “Investors”) for cash at a price per share of Common Stock (using the conversion price in the event of securities
convertible into Common Stock) less than that paid by Subscriber in a transaction intended to be exempt from registration
under the Securities Act, on or before the date of the initial public offering of the Company’s Common Stock pursuant
to an effective registration statement under the Securities Act (the “IPO”), Subscriber will have the right but
not the obligation to participate (the “Right of Participation”) in the Sale by purchasing Common Stock at the
same price as the Investors paid for the Common Stock, or, in the event of securities convertible into Common Stock, at the
conversion price, and in an amount equal to the aggregate purchase price paid by the Subscriber pursuant to the Subscription
Agreement divided by the price per share of the Company’s Common Stock, or in the event of securities convertible into
Common Stock, the conversion price, in the Sale. The Company shall provide the Subscriber with at least 15 business
days’ notice of any such Right of Participation and Subscriber shall accept or decline such Right of Participation by
notice to the Company within 10 business days of Subscriber receiving notice from the Company of the existence of such Right
of Participation. The Company shall provide the Subscriber, via e-mail, with all information made available to other
investors in the Private Placement.

 

     

     

    

 

2.                 
In the event that prior to, or concurrently with, the IPO the Company issues (except to employees, consultants or advisors)
Common Stock, or securities convertible into Common Stock, to Investors not affiliates of the Company (within the meaning of the
Securities Act) in one or more transactions on or before the date of the initial public offering of the Company’s Common
Stock pursuant to an effective registration statement under the Securities Act (the “IPO”) (each, a “Stock Placement”)
and with a price per share of the Company’s Common Stock (or conversion price in the event of securities convertible into
Common Stock) of less than $4.19 (the “Placement Price”), Subscriber shall receive as additional consideration pursuant
to the Subscription Agreement warrants (the “Stock Placement Warrants”) to purchase the Company’s Common Stock
in an amount equal to the aggregate purchase price paid by the Subscriber pursuant to the Subscription Agreement divided by the
Placement Price of the Stock Placement prior to the IPO having the lowest price per share. The exercise price of such Stock Placement
Warrants shall be 80% of the price per share of Common Stock in such Stock Placement. In the event that the IPO occurs after, and
not before, March 31, 2019, Subscriber shall receive as additional consideration pursuant to the Subscription Agreement warrants
(the “Late IPO Warrants”) to purchase the Company’s Common Stock in an amount equal to one-half the number of
common shares of the Company’s Common Stock originally purchased by the Subscriber pursuant to the Subscription Agreement
and with an exercise price equal to the IPO Price. Both the Stock Placement Warrants and Late IPO Warrants (together, the “Warrants”)
shall be exercisable at their holder’s sole discretion for a period of 10 years pursuant to their terms. Warrants shall be
governed by the form of Warrant attached as Exhibit A hereto.

 

3.                  The
Subscription Agreement, together with the other documents and exhibits referred to therein, constitute the entire agreement
among the parties and no party shall be liable or bound to any other party in any manner by any warranties, representations,
or covenants except as specifically set forth herein or therein. In all events, the terms and provisions of this Letter
Agreement shall be enforceable notwithstanding any conflicting term or provision set forth in any other agreements (including
the Subscription Agreement), governing documents (such as a certificate of incorporation or bylaws) or other documents or
instruments (each of the foregoing referenced herein as the “Other Documents”) entered into by the Company or
otherwise approved or adopted by the Company, regardless of whether such Other Document was executed, adopted or approved
simultaneously with or after this Letter Agreement. If any Other Documents (including, without limitation, the
Company’s certificate of incorporation or bylaws), currently or at any future time, impose any restrictions to the
foregoing rights, the Company shall amend such Other Documents or take such other appropriate action as shall be necessary so
that such restrictions do not apply. In the event of any conflict between any term or provision of this Letter Agreement and
any term or provision set forth in any Other Document, such term or provision of this Letter Agreement shall prevail over
such term or provision set forth in the Other Documents. Any notifications to the Subscriber pursuant to this Letter
Agreement shall also be delivered via e-mail to: mikepross@gmail.com and mross@JoCapLLC.com.

 

    -2-

     

    

 

4.                 
In the event that the Subscriber shall lose his investment instrument (such as a stock certificate or the Warrants), the
Company shall arrange for its replacement promptly upon the execution by the Subscriber of a standard affidavit of loss with fees
to any service providers, payable by the Subscriber, not to exceed the lesser of such service provider fees or $1,000.

 

5.                 
Section 6 of the Subscription Agreement is incorporated into this Letter Agreement by reference.

 

(signature page follows)

 

    -3-

     

    

 

IN WITNESS WHEREOF, the parties acknowledge
and agree that they have read this Letter Agreement, understand its contents, and have freely and voluntarily entered into it as
of the first date set forth above.

 

	 	INHIBIKASE THERAPEUTICS, INC.
	 	 
		By:	        /s/ Milton Werner
	 	 	Name:	Milton Werner, Ph.D.
	 	 	Title:	President & CEO

 

(signatures continue on following page)

 

    -4-

     

    

 

Accepted and Agreed as of the date first set forth above

 

Joseph Ventures Allium LLC

 

	By:	   
      /s/ Michael P. Ross	 
	 	Name:	Michael P. Ross	 
	 	Title:	 

 

    -5-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]